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Abstract
RNA interference (RNAi) has been successfully applied in suppression of hepatic cancer genes. In
hepatocelluar carcinoma cell, one methionine adenosyltransferase (MAT) isozyme, MATII was
found to have two catalytic subunits which were encoded by MAT2A and MAT2β respectively.
During tumorigeness of hepatocelluar carcinoma, expressions of the two genes were discovered
to be increased combining with a switch of MAT (form MATI to MATII), To figure out the role
played by MATII in hepatic cancer, In this study, for the first time we established a dual small
interfering RNA (siRNA) expression system, which could simultaneously express two different
siRNA molecules specifically targeting two genes. To test the effectiveness of this system, we
applied this approach to express simultaneously two different siRNA duplexes that specifically
target MAT2A and MAT2β genes of hepatocelluar carcinoma respectively in HepG2 cell. Results
indicated that dual siRNA could simultaneously inhibit the expression of MAT2A and MAT2β gene
by 89.5% and 97.8% respectively, In addition, dual siRNA molecules were able to significantly
suppress growth of hepatocelluar carcinoma cell in vitro as well as induce apoptosis which was
involved in arrest cell cycle at the G1/S checkpoint and the expressions of p21, p27 and Bax.
Introduction
It was demonstrated that a switch in MAT expression in
liver cancer (from MAT1A to MAT2A) played an impor-
tant pathogenetic role by facilitating liver cancer growth
[1] The importance of MAT expression on liver pheno-
typephenotype was confirmed in the MAT1A knockout
mouse model where replacement of MAT1A with MAT2A
resulted in eventual development of HCC [2,3]MAT1A is
expressed mostly in normal liver and it encodes theα1 sub-
unit. MAT2A encodes a catalytic subunit (α2) found in a
native MAT isozyme (MATII) which is associated with a
catalytically inactive regulatory subunit (β) encoded by
MAT2β, MAT2A predominates in hepatocelluar carci-
noma and facilitates liver cancer growth. It has been
proved that βsubunit was associated with cirrhosis and
cancer providing a proliferative advantage in hepatoma
cells through its interaction with MATIIα2 and down-reg-
ulation of SAMe levels[4] Recently hepatocyte growth fac-
tor (HGF) which is necessary for regeneration of hepatic
cell was found to promote proliferation of hepatoma cells
by up-regulating the expressions of MAT2A and MAT2β at
low density[5], leptin which was demonstrated to be
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mitogenic in human liver cancer cell lines HepG2 was also
related with increasing expressions of MAT2A and
MAT2β[6]. MAT2A and MAT2β must play important roles
in process of hepatocelluar carcinoma, siMAT2A and
siMAT2β had been constructed respectively [6,7]. To fur-
ther study their roles in hepatocelluar carcinoma, for the
first time we constructed a dual small interfering RNA
(siRNA) expression system which containing two siRNAs
(siMAT2A and siMAT2β) simultaneously mediated by
lentiviral vectors successfully, As a result growth-inhibi-
tion and apoptosis were induced by siRNA MAT2A and
MAT2β. Lentiviral vector encoding antisense targeting
HIV envelope sequence has been used for HIV treatment
in clinical trials with no obvious side effects [8,9]. Most
recently, lentiviral vector containing beta-globin gene has
been approved in phaseI/II clinical trials for human beta-
thalassemia and sickle cell anemia gene therapy[10]. We
hope that it will be used for clinical treatment of liver can-
cer.
Progression of cell cycle from G1 to S phase in mamma-
lian cell is controlled by the cyclin A, D, and E, which
binds to and activates different G1 kinases (CDK4/6 and
CDK2). The activation of cyclinD1/CDK4, cyclinD1/
CDK6 or/and cyclin E/CDK2 complex are required for
transition from G1 to S phase. The phosphorylation status
of retinoblastoma tumor suppressor protein (pRb) is reg-
ulated by cyclin D1/CDK4 or cyclinD1/CDK6 complex in
early G1 phase; as well as cyclin E/CDK2 complex in mid-
to-late G1 stage [11]. pRb is a negative regulator of cell
proliferation and a potential substrate for cyclin E/CDK2
complex at the G1-to-S phase transition of the cell cycle
[12]. Hypophosphorylated pRb in G1 is active for cell-
growth suppression, while its phosphorylated counterpart
in S/G2/M is inactive. Both p21 and p27 inhibit the activ-
ity of the cyclin D/CDK4, cyclinE/CDK2, and of cyclin A/
CDK2 complexes, whereby the phosphorylation of pRb is
blocked., In addition, p21 also blocks DNA replication
depending on proliferation cell nuclear antigen, resulting
in G1 arrest[13]. Bax was pro-apoptosis; Bcl-xL was anti-
apoptosis. Bax/Bcl-xL ratio plays important roles in the
apoptosis of HepG2[14]. It has been demonstrated that
induction mRNA of Bcl-xS by SAMe in HepG2 cells
resulted in apoptosis but SAMe had no effects on expres-
sion of Bcl-xL[15]. Here we want to know that if apoptosis
induced by siMAT2A and MAT2β was related with Bax and
Bax/Bcl-xL ratio.
Materials and methods
Constructs and Lentivirus Production
Constructs and Lentivirus production refers to a method
described previously [16,17]. MAT2A gene was cloned
into the Xho I and EcoR I sites of vector pEGFP-C1
(Genechem) which was driven by CMV to yield plasmid
pEGFP-C1-MAT2A. MAT2B gene was cloned into pEGFP-
C1 at EcoR II and XhoI sites to generate pEGFP-C1-
MAT2β. Two-pair of primers 5'-CCGCTC GAGCTATG
AAC GGACAGCTCAACG-3' (sense), 5'-CCGGAATTC-
GAATATTTAAGCTTTTT GGGCAC-3' (antisense) or 5'-
CCGCTCGAGCTATGAACGGACAGCTCAACG-3' (sense);
5'-CCGGAATTCG AATATTTAAGCTTTTTGGGCAC-3',
(antisense) were used to amplify the MAT2A and MAT2β
gene, respectively. The PCR products were then cloned
into AgeI and EcoRII sites of pGCL-GFP to generate plas-
mid pGCL-GFP-MAT2A and pGCL-GFP-MAT2β, in which
the MAT2A or MAT2β were fused in frame with the GFP
gene and the expression of the fusion gene was driven by
the CMV promoter. Four regions of the MAT2A gene and
four regions of the MAT2β gene were selected as the tar-
geted sequences of siRNA in this study. To construct single
siRNA expression vector, two 64 nt primers, each contain-
ing a 19 nt or 21 nt target sequence in the sense and anti-
sense forms from different regions of the MAT2A gene or
MAT2β gene as indicated below, were systhesized:
5'-GAGAGCTATTAGAGATTGT-3' (MAT2A 1siRNA);
5'-GGATACAATCTACCACCTA-3' (MAT2A 2siRNA);
5'-GTGAGAGAGAGCTATTAGA-3' (MAT2A 3siRNA);
5'-AATATCTGGTGACTGTTGC-3' (MAT2A 4siRNA);
5'-GCAGTTCATCACATCATTCAT-3' (MAT2β1siRNA);
5'-CCTTACAGAGAGGAAGACATA-3' (MAT2β2siRNA);
5'-GCTGTGACTGTTATGTTTGAT-3' (MAT2β3siRNA);
5'-GCCTCTCAACTTAATGTGGA-3' (MAT2β4siRNA).
Sense and antisense primers were then cloned into Psc
siRNA plasmid (Genechem) at EcoRI and XhoI sites after
annealing according to the manufacturer's instructions.
To generate the dual siRNA expression plasmid, two prim-
ers 5'-CCACGAGGCGTTCATCGAGG-3'(sense), and 5'-
AAGTCTTGTAGTCAAAACCT-3'(antisense) were designed
to amplify a DNA fragment containing U6 promoter and
MAT2A 2siRNA expression cassette from recombinant
plasmid Psc-U6-MAT2A. The PCR product was then
cloned into AatII and EcoRI sites of plasmid Psc-U6-
MAT2β1 to generate recombinant plasmid Psc-U6-
MAT2A/β, which carries two independent siRNA expres-
sion cassettes. Correct insertions of shRNA cassettes were
confirmed by restriction mapping and direct DNA
sequencing. Recombinant lentiviruses vectors were pro-
duced by co-transfecting 293T cells with the lentivirus
expression plasmid and packaging plasmids (pHelper 1.0
including gag/pol and pHelper 2.0 including VSVG) using
Lipofectamine 2000 or calcium phosphate method [18-Journal of Experimental & Clinical Cancer Research 2008, 27:72 http://www.jeccr.com/content/27/1/72
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20]. pGCL-GFP plasmids and Psc siRNA plasmid were co-
transfected in 293T cells, fluorescence-activated cell sort-
ing analysis of GFP positive in 293T cells, then MAT2A
2siRNA, MAT2β1 siRNA plasmid was chosen as effective
siRNA plasmid Infectious lentiviruses were harvested at
48 and 72 h post-transfection, centrifuged to get rid of cell
debris, and then filtered through 0.22-lm cellulose acetate
filters[21]. The infectious titer was determined by fluores-
cence-activated cell sorting analysis of GFP positive in
293T cells. The virus titers were at the range of 109 trans-
ducing units/ml medium. lentiviruses vectors containing
MAT2A 2siRNA, MAT2β1 siRNA and both of them simul-
taneous was constructed respectively, which was desig-
nated LV-siMAT2A, LV-siMAT2β and LV-siMAT2A/2β.
Cell culture and transfection
Human hepatocelluar cancer HepG2 cell lines (purchased
from Classic Specimen Culture and Storage Centre in
Wuhan University) The cell lines were grown in 5% CO2
saturated humidity at 37°C and cultured as monolayers in
RPMI 1640 supplemented with penicillin/streptomycin, 2
mM glutamine and 10%FBS. Cells were always detached
using Trypsin-EDTA. for 4–5 days and then subcultured at
1×105 cells per well into six-well tissue culture plates. After
72 h of culture, the cells were transfected with siMAT2A
and2β formulated into liposomes according to the manu-
facturer's instructions (TransMessengerTM, Qiagen,
Valencia, CA). lentiviruses concentration was 0.5μl per
well, and the final volume of culture medium was 2 mL
per well. Growth curve was drafted. Untreated cell was
used as control.
RT-PCR and Semi-quantitative PCR measurement
HepG2 cells were transfected with LV-siMAT2A, LV-
siMAT2β and LV-siMAT2A/2β respectively. At 72 h after
transfection, total RNA was extracted with TRIzol reagent
according to the protocol provided by the manufacturer
(Invitrogen, Carlsbad, CA, USA). Sequences of sense
primer and antisense primer were seen as Table 1. Reverse
transcription PCR (RT-PCR) reactions were performed as
follows: cDNA was amplified for 25 cycles at 95°C for 5
min, 94°C for 1 min, 60°C for 45 s, 72°C for 1 min and
72°C for 10 min. MAT2β gene cDNA was amplified for 45
cycles at 95°C for 15 s, 94°C for 5 s, 60°C for 30 s, 72°C
for 30 s and 72°C for 10 min. The PCR reaction for β-actin
cDNAs was performed with 30 cycles and the reaction
conditions were: denaturation at 94°C for 1 min, anneal-
ing at 53°C for 2 min, and extension at 72°C for 3 min.
Semi-quantitative PCR for Bax: denaturation at 94°C for
45 s, annealing at 58°C for1 min, and extension at 72°C
for 1 min. p21:95°C for30 s, 55°C for 90 s and 72°C for
120 s using 30 cycles, p27:94°C 30 s, 55°C 30 s, or 57°C
30 s, 72°C 60 s. PCR products were analyzed through 1%
agarose gel electrophoresis and following ethidium bro-
mide staining.
Western-blot analysis
Cells were collected after different treatments, rinsed in
ice-cold PBS, 15 mins, and lysed in lysis buffer containing
50 mmol/L HEPES (pH 7.9), 0.4 mol/L NaCl, 1 mmol/L
EDTA, 2 Ag/mL leupeptin, 2 Ag/mL aprotinin, 5 Ag/mL
benzamidine, 0.5 mmol/L phenylmethylsulfonylfluoride,
and 1% NP40. The lysates were centrifuged at 14,000 rpm
to remove any cellular debris. Protein concentrations of
the lysates were determined by the Bio-Rad Dc protein
assay system which was 2 μg/μl. Equal amount of protein
was separated by12% SDS-PAGE, transferred to PVDF
membrane, and blocked with 5% nonfat dry milk in TBS/
Tween 20 (0.05%, v/v) for 1 hour at room temperature.
The membrane was incubated with primary antibody
overnight. anti-GAPDH anti-p21, anti-p27 and anti-Bax
antibodies were obtained from Santa Cruz Biotech. Anti-
Table 1: Sequences of sense primer and antisense primer
β-actin mRNA (300 bp)
β-actin sense primer 5'-CTGGGGCGCCCCAGGCACCA-3'
antisense primer 5'-CTCCTTAATGTCACGCACG ATTTC-3'
MAT2A mRNA (287 bp)
MAT2A sense primer 5'-CCACGAGGCGTTCATCGAGG-3'
antisense primer 5'-AA GTCTT GTAGTC AAAACCT-3'
MAT2β mRNA (324 bp)
MAT2β sense primer 5'-ACAGAG AGGAAGACATACCAG-3'
antisense primer 5'-GTTCATTGCCAGACCAGTG-3'
Bax mRNA
Bax sense primer 5'-ACCAAGAAGCTGAGCGAGTGTC-3'
antisense primer 5'-TGTCCA GCCCATGATGGTTC-3'[22]
p21 mRNA
p21 sense primer 5'-AAGACCATGTGGACCTGTCA-3'
antisense primer 5'-AGGAAGTAGCTGGCATGAAG-3' [23]
p27 mRNA
p27 sense primer 5'-AAG TGGCATGTTTTGTGCATTT-3'
antisense primer 5'-GCT CAG TATGCAACC TTTTAAGCA-3' [24]Journal of Experimental & Clinical Cancer Research 2008, 27:72 http://www.jeccr.com/content/27/1/72
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MAT2A antibody were obtained from Genway company.
Anti-MAT2β was purchased from Abnova corporation
(Tai wan, China). After washing, the membrane was incu-
bated with secondary antibody (diluted 1:4,000; Amer-
sham Pharmacia Biotech, Arlington Heights, IL) for 1
hour. Following several washes, the blots were developed
by enhanced chemiluminescence. (Amersham, Arlington
Heights, IL). Each experiment was repeated at least twice
with similar results.
Cells apoptosis analysis by Flow cytometry
The inducing apoptosis effects of LV-siMAT2A, LV-
siMAT2β and LV-siMAT2A/2β on human hepatocelluar
cancer cells and were analyzed by Flow cytometry. Briefly,
Cells were incubated with LV-siMAT2A, LV-siMAT2β, LV-
siMAT2A/2β and vehicle alone for 72 h, fixed with 70%
ethanol treated with RNase (100 lg/ml, Sigma Chemical
Co., St. Louis, MO), and stained with propidiumiodide
(100 lg/ml, Sigma) for 30 min on ice. DNA content in the
cells was analyzed by a flow cytometer (Epics XL; Beck-
man Coulter, Miami, FL).
Assay of Hepatic SAMe levels
Hepatic SAMe levels were measured using a method
described previously[25] with slight modifications. Liver
specimens were homogenized in phosphate-buffered
saline, and an aliquot was saved for protein assay. The rest
was treated with 100 μl of 1 M perchloric acid (PCA) onice
for 5 min and centrifuged at 1000 g for 15 min at 4°C. The
aqueous layer was quantitatively removed, neutralized
with 3 M KOH, and centrifuged at 3000 g for 10 min at
4°C. SAMe levels were deter mined in the neutralized PCA
extracts by HPLC (LC-10ATVP pump, SCL-10AVP system
control) with a SPD-10AVP UV detector and a SIL-
10ADVPautosampler (Shimadzu) using a Partisil SCX 10
μm column (25 × 0.44 cm i.d.; Whatman Chem. Sep.
Maidstone, Cleveland, OH). SAMe was eluted isocrati-
cally at 1 ml/min with 0.19 MNH4H2PO4 adjusted to pH
2.6 with 2 M H3PO4. SAMe levels were calculated using
standard curve of SAMe prepared at the same time as the
samples and are reported as nmol/mg protein.
Statistical methods
All results are expressed as mean ± SD, and statistical anal-
yses of the data is performed using ANOVA Post Hoc Dun-
nett t test. All p values are based on two-sided hypothesis
testing, P < 0.05 is considered significant.
Results
Suppression of cell growth caused by LV-siMAT2A, LV-
siMAT2β and LV-siMAT2A/2β
To assess the potential effects of Lentivirus vectors RNAi-
mediated MAT2A and MAT2β silencing on cell growth,
LV-siMAT2A, LV-siMAT2β and LV-siMAT2A/2β were
transfected into respectively, 72 hours after infection at
multiplicity of infection of 25 through estimating GFP
expression under a fluorescent microscope (Figure 1).
Cells were counted every day for 5 days after transfections,
growth curve was drafted. As a result, growth-inhibition
effects were produced by LV-siMAT2A, LV-siMAT2β and
LV-siMAT2A/2β, in which caused by LV-siMAT2A/2β was
most evident (p < 0.01) and LV-siMAT2A was most
slight(p < 0.05) (Figure 2)
Knockdowns of MAT2A, MAT2β and both by LV-siMAT2A, 
LV-siMAT2β and LV-siMAT2A/2β respectively could Induce 
Apoptosis in human hepatocelluar cancer cell
To investigate the effects of LV-siMAT2A, LV-siMAT2β and
LV-siMAT2A/2β on cell apoptosis. The distribution of cell
cycle was determined by flow cytometry analysis. After
HepG2 cells were transfected with LV-siMAT2A, LV-
siMAT2β and LV-siMAT2A/2β for 72 h, the percentage of
both S and G2/M phase were decreased 72 h after LV-
siMAT2A, LV-siMAT2β and LV-siMAT2A/2β treatment,
and the percentage of G0/G1 phase was increased, (Fig-
ure. 3). The expressions of p21 and Bax were up-regulated
by LV-siMAT2A, LV-siMAT2β and LV-siMAT2A/2β. p27
which was up-regulated by LV-siMAT2β and LV-siMAT2A/
2β but not by LV-siMAT2A. the mRNA levels of p21 and
Bax were highest induced by LV-siMAT2A/2β, but that
there was no difference between that caused by caused LV-
siMAT2A LV-siMAT2β (Figure 4). Western-blot was
applied to assay the expressions of Bax, p27 and p21, After
HepG2 cells were transfected with LV-siMAT2A, LV-
siMAT2β and LV-siMAT2A/2β for 72 h, GAPDH was used
as control, It was showed in figure 5 that protein of Bax
was increased by LV-siMAT2β, LV-siMAT2Aand LV-
siMAT2A/2β, which was highest after cells was deal with
LV-siMAT2A/2β, protein of p27 was increased by LV-
siMAT2β and LV-siMAT2A/2β but not by LV-siMAT2A,
The protein of p21 does not change compared with con-
trol.
Lentivirus-Mediated RNAi Efficiently Suppressed MAT2A 
and MAT2β mRNA in HCC HepG2 cell in vitro
After HepG2 cells were transfected with LV-siMAT2A, LV-
siMAT2β and LV-siMAT2A/2β for 72 h, RT-PCR was per-
formed to determined the mRNA of MAT2A and MAT2β.
As it showed in figure 6 mRNA of MAT2A and MAT2β
were knocked down by LV-siMAT2A, LV-siMAT2β by
85.5% and 94.0% respectively, and both of them were
suppressed LV-siMAT2A/2β by 89.5% and 97.8% simulta-
neously compared with control which was untreated. We
found that LV-siMAT2A had no effect on mRNA of
MAT2β, on the other hand, LV-siMAT2β had no impact
on mRNA of MAT2A.Journal of Experimental & Clinical Cancer Research 2008, 27:72 http://www.jeccr.com/content/27/1/72
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Lentivirus-Mediated RNAi Efficiently Suppressed MAT2A 
and MAT2β protein in HCC HepG2 cell in vitro
In order to figure out the suppression efficiencies caused
by LV-siMAT2A, LV-siMAT2β and LV-siMAT2A/2β, West-
ern-blot was applied to detect protein of MAT2A and
MAT2β after HepG2 cells were transfected with LV-
siMAT2A, LV-siMAT2β and LV-siMAT2A/2β for 72 h. It
was indicated in figure 7 that the expressions of MAT2A
and MAT2β were inhibited by LV-siMAT2A and LV-
siMAT2β respectively at protein level by 99.4% and
60.2%, both of them were suppressed by LV-siMAT2A/2β
by 98.6% and 90.8%. We discovered that LV-siMAT2A did
not have impact on protein expression of MAT2β, and LV-
siMAT2β also did not have effect on impact on protein
expression of MAT2A too.
Intracellular SAMe Contents were changed by LV-
siMAT2A, LV-siMAT2β and LV-siMAT2A/2β
The changes in MAT genes expression are likely to cause
changes in the production of SAMe. We analyzed the
effects of silencing MAT2A and MAT2β by different Lenti-
virus-Mediated RNAi on SAMe production by measuring
levels of SAMe a in HCC cell. As a result, Intracellular
SAMe content was decreased by LV-siMAT2A and
increased by LV-siMAT2β as well as LV-siMAT2A/2β, com-
pared with control. (Figure 8)
shows that HepG2 cells were without treatment (untreat), and infected with LV-siMAT2A, ALV-siMAT2β and LV-siMAT2A/2β Figure 1
shows that HepG2 cells were without treatment (untreat), and infected with LV-siMAT2A, ALV-siMAT2β and 
LV-siMAT2A/2β. The cells were infected (MOI = 25), GFP expression and the phase contrast images of same areas were 
taken after 72 h.
indicates that HepG2 cells were without treatment (untreat),  and infected with LV-siMAT2A, ALV-siMAT2β and LV- siMAT2A/2β, in the following 5 days cells were counted  every day, then growth curve was drafted Figure 2
indicates that HepG2 cells were without treatment 
(untreat), and infected with LV-siMAT2A, ALV-
siMAT2β and LV-siMAT2A/2β, in the following 5 days 
cells were counted every day, then growth curve was 
drafted.Journal of Experimental & Clinical Cancer Research 2008, 27:72 http://www.jeccr.com/content/27/1/72
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Discussion
Methionine adenosyltransferase enzymes (MAT I, MAT II,
and MAT III) have been demonstrated to play roles in
hepatic cirrhosis and cancer. [26,27] Two different genes,
MAT1A and MAT2A, encode for two homologous MAT
catalytic subunits, α1 andα2. [28-30] MAT1A is expressed
mostly in the normal adult liver, and it encodes theα1 sub-
unit discovered in two native MAT isoenzymes, which are
either a dimer (MAT III) or tetramer (MAT I) of this single
subunit.[30] The gene MAT2A encodes for the α2 catalytic
subunit in the MATII isoform. The gene MAT2β, encodes
for a β regulatory subunit that regulates the activity of
MATII by lowering inhibition constant (Ki) for SAMe and
Michaeli's constant (Km) for methionine [1], MAT2A and
its gene product also predominate in the fetal liver and are
progressively replaced by MAT1A during development in
normal adult liver [31,32] but in liver cirrhosis and can-
cer, expressions of MAT2A and MAT2β are both increased.
MAT1A gene is specifically silenced by hypermethylation
in human cirrhosis, which leads to a marked reduction of
SAMe synthesis, We discovered the SAMe content could
be decreased by knocking down MAT2A and increased by
knocking down MAT2β which were in agreement with the
results of Komal[6]. And we further discovered that the
level of SAMe was increased when MAT2A and MAT2β
were suppressed by LV-siMAT2A/2β simultaneously. This
may be related with decreased expression of MAT2β
which was believed to regulate MATII activity by increas-
ing the sensitivity of the enzyme to feedback inhibition by
SAMe[33]. It has been demonstrated that the type of MAT
expressed by the cell significantly influenced the rate of
cell growth. Further research discovered that expression of
MAT2A not only correlated with liver cancer cell prolifer-
ation but also was necessary for this process [34]. The β
subunit was associated with cirrhosis and cancer provid-
ing a proliferative advantage in hepatoma cells through its
interaction with MAT II α2 and down-regulation of SAMe
levels[4]. That is to say that both MAT2A and MAT2β can
facilitate liver cancer growth and it was interested to find
that when MAT2A and MAT2β were suppressed by LV-
siMAT2A and LV-siMAT2β respectively, apoptosis and
growth-inhibition were both induced, LV-siMAT2A had
no effect on expression of MAT2β and LV-siMAT2β had no
effect on expression of MAT2A at either mRNA or protein
levels. We hypothesized that MAT2A and MAT2β may
influence growth of liver cancer independently, this is the
reason why we want to construct the dual small interfer-
shows that HepG2 cells without treatment (U), and were  infected with LV-siMAT2A(2A), LV-siMAT2β (2β) and LV- siMAT2A/2β (2A/2β), cell apoptosis was induced by LV- siMAT2A, ALV-siMAT2β and LV-siMAT2A/2β, as showed in  the picture "AP" stands for apoptotic peak, There was most  cells into apoptosis after cells were deal with LV-siMAT2A/ 2β, and G1/S arrest was discovered Figure 3
shows that HepG2 cells without treatment (U), and 
were infected with LV-siMAT2A(2A), ALV-siMAT2β 
(2β)and LV-siMAT2A/2β (2A/2β), cell apoptosis was 
induced by LV-siMAT2A, ALV-siMAT2β and LV-
siMAT2A/2β, as showed in the picture "AP" stands 
for apoptotic peak, There was most cells into apop-
tosis after cells were deal with LV-siMAT2A/2β, and 
G1/S arrest was discovered. It was demonstrated in the 
Fig. 3 that cell apoptosis caused by LV-siMAT2A/2β was 
increased in human hepatocelluar cancer cells HepG2 com-
pared to that induced by LV-siMAT2A, ALV-siMAT2β (P < 
0.01) and control, but they all had no difference between LV-
siMAT2A and LV-siMAT2β.
displayed that HepG2 cells without treatment (U), and were  infected withLV-siMAT2β (2β), A LV-siMAT2A(2A)and LV- siMAT2A/2β (2A/2β) Figure 4
displayed that HepG2 cells without treatment (U), 
and were infected withLV-siMAT2β (2β), A LV-
siMAT2A(2A)and LV-siMAT2A/2β (2A/2β). PCR was 
applied to assay the expressions of Bax, p27 and p21 β-actin 
was used as control, It was showed in Fig 7 that mRNA of 
Bax and p21 was increased by LV-siMAT2β, ALV-siMAT2A 
and LV-siMAT2A/2β, which were both highest after treating 
with LV-siMAT2A/2β, mRNA of p27 was increased by LV-
siMAT2β and LV-siMAT2A/2β but not by LV-siMAT2AJournal of Experimental & Clinical Cancer Research 2008, 27:72 http://www.jeccr.com/content/27/1/72
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ing RNA expression system targeting to MAT2A and
MAT2β simultaneously. As a result we came to find that
the effect of growth-inhibition and apoptosis caused by
LV-siMAT2A/2β was more than that caused by LV-
siMAT2A and LV-siMAT2β, The changes in MAT genes
expression are likely to cause changes in the production of
SAMe. SAMe plays an important role in growth and apop-
tosis of hepatic cell [35,36] But it was showed in our
research that both LV-siMAT2A and LV-siMAT2β, as well
as LV-siMAT2A/2β can induce growth-inhibition and
apoptosis in hepatic cancer HepG2 cell in spite of level of
SAMe. We, therefore, considered that besides regulating
intracellular SAMe content there must be another path-
way for MAT2A and MAT2β to make impact on cell
growth and apoptosis. As a result we revealed that the
expression of p21 that inhibited G1 to S phase transition
was up-regulated and Bax which was regarded as pro-
apoptotic gene [37] was increased by LV-siMAT2A LV-
siMAT2β and LV-siMAT2A/2β, the mRNA levels of p21
and Bax were highest induced by LV-siMAT2A/2β, but that
there was no difference between that caused by caused by
LV-siMAT2A and LV-siMAT2β. The expression of Bax may
be related with that of MAT2A and MAT2β, because Leptin
was demonstrated to be mitogenic in human liver cancer
cell lines HepG2 which was associated with increasing of
MAT2A and MAT2β simultaneously[6] and Leptin has
been proved to induce proliferation and anti-apoptosis in
human hepatocarcinoma cells by up-regulating cyclin D1
and down-regulating Bax via a Janus kinase 2-linked path-
way[38]. Although had no effects on expression of Bcl-xL,
but expression of Bax was increased, Bax/Bcl-xL ratio was
changed so apoptosis was induced. On the other hand, it
was demonstrated by us that p27 which was believed to be
cell-cycle regulators at S phase cell-cycle arrest [39-42] was
up-regulated by LV-siMAT2β and LV-siMAT2A/2β but not
by LV-siMAT2A, To agree with this that the percentage of
S phase in cell treated with LV-siMAT2A was more than
that caused by LV-siMAT2β and LV-siMAT2A/2β and
grow-inhibition effect was more evident in hepatic cancer
HepG2 cell transfected with LV-siMAT2β and LV-
siMAT2A/2β. We further applied western-blot to assay the
proteins of Bax, p21 and p27, we found that protein of
Bax was increased by LV-siMAT2A, LV-siMAT2β and LV-
siMAT2A/2β, that of p27 was up-regulated by LV-siMAT2β
and LV-siMAT2A/2β but not by LV-siMAT2A, the expres-
sion of p21 was not changed by all of them at protein
level, this may because p21 is regulated mainly at tran-
scriptional level by p53-dependent or independent mech-
anisms[43]. Whereas p27 is regulated predominantly at
post-translational level, especially protein degrada-
tion[44]. We also came to a conclusion that the expression
of p27 was related with MAT2β but not MAT2A and the
expression of p21 was regulated by both MAT2A and
MAT2β.
showed that HepG2 cells without treatment (U), and were  infected withLV-siMAT2β (2β), A LV-siMAT2A(2A)and LV- siMAT2A/2β (2A/2β), LV-siMAT2β, ALV-siMAT2A and LV- siMAT2A/2β Figure 5
showed that HepG2 cells without treatment (U), and 
were infected withLV-siMAT2β (2β), A LV-
siMAT2A(2A)and LV-siMAT2A/2β (2A/2β), LV-
siMAT2β, ALV-siMAT2A and LV-siMAT2A/2β. West-
ern-blot was applied to assay the expressions of Bax, p27 and 
p21 GAPDH was used as control, It was showed in Fig 8 that 
protein of Bax was increased by LV-siMAT2β, ALV-siMAT2A 
and LV-siMAT2A/2β, which was highest after treating with 
LV-siMAT2A/2β, protein of p27 was increased by LV-
siMAT2β and LV-siMAT2A/2β but not by LV-siMAT2A, The 
expression of p21 does not change.
demonstrated that after HepG2 cells were done with differ- ent treatment Figure 6
demonstrated that after HepG2 cells were done with 
different treatment. RT-PCR was performed to decide 
the mRNA level of MAT2A and MAT2β, 1 means untreated 
cells; 2, 3 and 4 stands for doing withLV-siMAT2A/2β, LV-
siMAT2A and LV-siMAT2β respectively. It was showed in the 
Fig 4 that MAT2A and MAT2β were suppressed byLV-
siMAT2A and LV-siMAT2β respectively and by LV-siMAT2A/
2β simultaneously. LV-siMAT2A has on effect on expression 
of MAT2β, vice versa.Journal of Experimental & Clinical Cancer Research 2008, 27:72 http://www.jeccr.com/content/27/1/72
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In total, we had a conclusion that the dual small interfer-
ing RNA expression system targeting to MAT2A and
MAT2β simultaneously was constructed successfully, LV-
siMAT2A/2β can lead to grow-inhibition and cell apopto-
sis which is more than LV-siMAT2A and LV-siMAT2β, this
may be a new way for the therapy of hepatic cancer in the
future.
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